

UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION

ADMINISTRATIVE PROCEEDING
File No. 3-20550

<p>In the Matter of</p> <p>Calmare Therapeutics Incorporated.,</p> <p>Respondent.</p>
--

RESPONDENT’S SUPPLEMENT TO ITS SUBMISSION OF EXPERT DISCLOSURES

Pursuant to Rules of Practice 161 and 250, Calmare Therapeutics Incorporated (“Respondent” or “Calmare”), by and through its undersigned counsel, hereby supplements its Designation of Expert Witness Testimony submitted January 25, 2022 pursuant to 17 C.F.R. § 201.222(b) expert disclosures, and states as follows:

Peter Brennan. The Declaration of Peter Brennan in Support of Respondent’s Opposition to Division of Enforcement’s Motion For Summary Disposition is submitted herewith as Exhibit B. Mr. Brennan’s qualifications consist of his experience and background as described in his Declaration. There no other proceedings in which he has given expert testimony during the previous four years and there are no publications that he has authored in the previous ten years. Mr. Brennan will not receive any compensation for his testimony.

Dated: January 28, 2022

Respectfully submitted,

/s/ Paul L. Vorndran

Paul L. Vorndran
Alan Talesnick
Jones & Keller, P.C.
1675 Broadway, 26th Floor
Denver, Colorado 80202
pvorndran@joneskeller.com
atalesnick@joneskeller.com
Counsel for Respondent Calmare Therapeutics
Incorporated

CERTIFICATE OF SERVICE

I hereby certify that I caused true copies of The Respondent's Supplement To Its Submission Of Expert Disclosures to be served on the following on January 28, 2022, in the manner indicated below:

Via eFap:

Office of the Secretary

By Email:

Christopher Bruckmann (202) 551-5986
Gina Joyce (202) 551-4850
bruckmannc@sec.gov
joyceg@sec.gov
Securities and Exchange Commission
100 F Street, N.E. Washington, D.C. 20549

Counsel for Division of Enforcement

/s/ Paul L. Vorndran
Paul L. Vorndran